ReviewInternational journal of medical sciences2026
Metabolomics in the Prediction and Early Diagnosis of Type 2 Diabetes Mellitus: Advances and Applications.
Review in International journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection and intervention can prevent the onset and progression of type 2 diabetes mellitus (T2DM); however, achieving early diagnosis and accurate prediction remains challenging. Metabolomics, a potent diagnostic tool in systems biology, makes it possible to systematically identify important biomarkers linked to type 2 diabetes, which provides vital proof for risk assessment and early diagnosis. This review summarizes research advances in metabolomics for T2DM prediction and early detection since 2010 by incorporating both the reported prospective and cross-sectional metabolic evidence, with a focus on putative biomarkers and their metabolic characteristics identified across diverse biological samples. Furthermore, it highlights the unique advantages of metabolomics in T2DM early warning, aiming to offer novel insights for future research on personalized prevention and early diagnostic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.